At Washington Patent Panel, Academia and Private Sector Duke It Out | GenomeWeb

WASHINGTON, Sept. 24 - At a consumer-oriented panel discussion about the merits of gene-related patents, two salient points managed to bubble to the surface: Academic types and corporate folks may agree that patents are the linchpins of innovation, but they disagree over what R&D stage a patent should be awarded.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.